Michael Myers - 29 May 2025 Form 4/A - Amendment Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role: Chief Executive Officer, Director
Signature: /s/ Michael Myers
Issuer symbol: QNRX
Transactions as of: 29 May 2025
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 13 Jun 2025, 20:06:37 UTC
Date Of Original Report: 02 Jun 2025
Previous filing: 27 Dec 2024
Next filing: 06 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Myers Michael	Chief Executive Officer, Director	C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN	/s/ Michael Myers	13 Jun 2025	0001959547

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	QNRX	Share Option (Right to Buy)	Award	$0	+42,857		$0.000000	42,857	29 May 2025	ADS	42,857	$9.07	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.
F2	The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.